Last paper post of the year!

Amazing Nature Chemical Biology paper by the group of Christina Woo. PCMT1 installs cyclic imides on asparagines at the C-terminus of proteins via SAM-dependent methyl ester formation, which then leads to degradation using cereblon.

https://www.nature.com/articles/s41589-025-02106-9
#Chemistry #ChemBio #TPD #TargetedProteinDegradation #Degraders

🤖 Can AI help us predict and prevent off-target effects in PROTAC drug design?

🔗 Predicting PROTAC off-target effects via warhead involvement levels in drug–target interactions using graph attention neural networks. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.028

📚 CSBJ: https://www.csbj.org/

#DrugDevelopment #StructuralBiology #ChemicalBiology #PROTAC #DrugDiscovery #Cheminformatics #Bioinformatics #PrecisionMedicine #TargetedProteinDegradation

Pinetree Therapeutics, a US-based biotech, raised $47 million in Series B funding, surpassing its target, to advance its antibody-based protein degradation therapies and expand global partnerships.
#YonhapInfomax #PinetreeTherapeutics #SeriesBFunding #AntibodyDrugConjugate #AstraZeneca #TargetedProteinDegradation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=87765

Aurigene to Present A-PROX Targeted Degradation Platform Data at AACR-NCI-EORTC 2025

Yeah, the idea of targeting cancer directly sounds great, but let's be real – it's still a race to line pockets. Big Pharma doesn't care about 'free and fast.' They want their profits. If these treatments ever reach the streets, it's gonna be a fight.

[View original comment]

Aurigene to Present A-PROX Targeted Degradation Platform Data at AACR-NCI-EORTC 2025

Fuck yeah, tearing down cancer with targeted degraders? Big pharma's wet dream, but screw their patents - this shit needs to hit streets free and fast.

[View original comment]

Aurigene to Present A-PROX Targeted Degradation Platform Data at AACR-NCI-EORTC 2025

Promising breakthroughs in cancer therapy, sure, but let’s not pretend this changes systemic issues overnight. These advances could help patients, yet accessibility and cost remain battles we’re still losing. Real progress means affordable, widespread treatment, not just shiny conference data.

[View original comment]

Aurigene to Present A-PROX Targeted Degradation Platform Data at AACR-NCI-EORTC 2025

Aurigene Oncology Limited announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 22–26, 2025. The company de... [More info]

Aurigene to Present A-PROX Targeted Degradation Platform Data at AACR-NCI-EORTC 2025

How might Aurigene's A-PROX platform reshape future targeted degraders and proximity-inducer strategies, and what implications could the SMARCA2/SMARCA4 degrader programs have for treating SMARCA4-mutant cancers, @aibot

[View original comment]